CO2023004100A2 - Virus de la diarrea epidémica porcina atenuado - Google Patents

Virus de la diarrea epidémica porcina atenuado

Info

Publication number
CO2023004100A2
CO2023004100A2 CONC2023/0004100A CO2023004100A CO2023004100A2 CO 2023004100 A2 CO2023004100 A2 CO 2023004100A2 CO 2023004100 A CO2023004100 A CO 2023004100A CO 2023004100 A2 CO2023004100 A2 CO 2023004100A2
Authority
CO
Colombia
Prior art keywords
diarrhea virus
epidemic diarrhea
porcine epidemic
attenuated porcine
attenuated
Prior art date
Application number
CONC2023/0004100A
Other languages
English (en)
Inventor
Yanhong Hou
Xiaosai Ruan
Hongxin Yu
Can Liu
Haiyan Li
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2023004100A2 publication Critical patent/CO2023004100A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La divulgación proporciona una proteína espicular truncada en el terminal C de PEDV. También se proporcionan secuencias de ácidos nucleicos que la incluyen y un virus que la comprende, así como métodos de uso.
CONC2023/0004100A 2020-09-29 2023-03-29 Virus de la diarrea epidémica porcina atenuado CO2023004100A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011048314.0A CN114315985A (zh) 2020-09-29 2020-09-29 减毒猪流行性腹泻病毒
PCT/US2021/051807 WO2022072215A2 (en) 2020-09-29 2021-09-23 Attenuated porcine epidemic diarrhea virus

Publications (1)

Publication Number Publication Date
CO2023004100A2 true CO2023004100A2 (es) 2023-04-05

Family

ID=78372132

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0004100A CO2023004100A2 (es) 2020-09-29 2023-03-29 Virus de la diarrea epidémica porcina atenuado

Country Status (15)

Country Link
EP (1) EP4221748A2 (es)
JP (1) JP2023543033A (es)
KR (1) KR20230079021A (es)
CN (2) CN114315985A (es)
AR (1) AR123646A1 (es)
AU (1) AU2021353430A1 (es)
BR (1) BR112023005715A2 (es)
CA (1) CA3197074A1 (es)
CL (1) CL2023000913A1 (es)
CO (1) CO2023004100A2 (es)
EC (1) ECSP23029637A (es)
MX (1) MX2023003651A (es)
PE (1) PE20240081A1 (es)
TW (1) TW202221012A (es)
WO (1) WO2022072215A2 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US3914408A (en) 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
JP3011939B2 (ja) 1987-03-02 2000-02-21 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 組換えミコバクテリア・ワクチン
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
JPH05504067A (ja) 1990-02-26 1993-07-01 コモンウェルス　サイエンティフィック　アンド　インダストリアル　リサーチ　オーガナイゼイション 大腸菌及びマイコバクテリアのためのシャトルプラスミド
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
CA2110682A1 (en) 1991-06-06 1992-12-10 Charles K. Stover Induction of ctl responses to foreign antigens expressed in mycobacteria
ATE235959T1 (de) 1994-04-15 2003-04-15 Univ Temple Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
CN1688606A (zh) 2002-08-12 2005-10-26 昆士兰医学研究所理事会 含有辅助t细胞和b细胞表位的新的免疫原性脂肽
CN1688605B (zh) 2002-08-12 2011-01-12 昆士兰医学研究所理事会 包含辅助t细胞和细胞毒性t淋巴细胞(ctl)表位的新免疫原性脂肽
WO2004026024A2 (en) 2002-09-20 2004-04-01 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
KR20080013850A (ko) 2005-02-08 2008-02-13 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역원성 분자
WO2007127936A2 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods

Also Published As

Publication number Publication date
BR112023005715A2 (pt) 2023-05-02
JP2023543033A (ja) 2023-10-12
CN114315985A (zh) 2022-04-12
CL2023000913A1 (es) 2023-11-24
EP4221748A2 (en) 2023-08-09
PE20240081A1 (es) 2024-01-16
AU2021353430A1 (en) 2023-05-11
AR123646A1 (es) 2022-12-28
MX2023003651A (es) 2023-04-19
WO2022072215A2 (en) 2022-04-07
TW202221012A (zh) 2022-06-01
AU2021353430A9 (en) 2024-01-18
WO2022072215A3 (en) 2022-07-07
CN116635521A8 (zh) 2023-11-03
ECSP23029637A (es) 2023-07-31
CN116635521A (zh) 2023-08-22
CA3197074A1 (en) 2022-04-07
KR20230079021A (ko) 2023-06-05

Similar Documents

Publication Publication Date Title
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CY1117797T1 (el) Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων
CO2017004318A2 (es) Variantes de interferon α2b
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
AR091735A1 (es) Complejo de factor viii con xten y proteina factor de von willebrand (vwf) y usos del mismo
BRPI0516356A (pt) terapia à base de levedura para infecções crÈnicas da hepatite c
PE20091218A1 (es) Anticuerpo anti-glipicano 3 con cinetica en plasma mejorada
CL2011002453A1 (es) Compuestos derivados de diazol u oxazol-pirrol o pirrolciclopropil condensados sustituidos, inhibidores de la función de la proteína ns5a codificada por el virus de la hepatitis c (vhc); composición farmacéutica; y su uso para el tratamiento de una infección por vhc.
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
EA200870237A1 (ru) Последовательности пептидов и композиции
AR107385A1 (es) Proteína tolerante a herbicidas, su gen codificador y su uso
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
CL2010001569A1 (es) Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro.
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
CL2022001492A1 (es) Nuevos inhibidores de braf como rompedores de la paradoja
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CO2023004100A2 (es) Virus de la diarrea epidémica porcina atenuado
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes